Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia

Published:2016-01-07 Issue:1 Volume:127 Page:79-86
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Byrd John C.¹²,Flynn Joseph M.¹,Kipps Thomas J.³,Boxer Michael⁴⁵,Kolibaba Kathryn S.⁵⁶,Carlile David J.⁷,Fingerle-Rowson Guenter⁸,Tyson Nicola⁹,Hirata Jamie¹⁰,Sharman Jeff P.⁵¹¹

Affiliation:

1. Division of Hematology and Comprehensive Cancer Center and

2. Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH;

3. Moores Cancer Center, University of California San Diego, La Jolla, CA;

4. Arizona Oncology Associates, Tucson, AZ;

5. US Oncology Research, Vancouver, WA;

6. Northwest Cancer Specialists, Vancouver, WA;

7. Roche Innovation Center, Welwyn Garden City, United Kingdom;

8. F. Hoffmann-La Roche, Pharma Development Oncology, Basel, Switzerland;

9. F. Hoffmann-La Roche Ltd., Welwyn Garden City, United Kingdom;

10. Genentech Inc., South San Francisco, CA; and

11. Willamette Valley Cancer Institute and Research Center, Eugene, OR

Abstract

Key Points Obinutuzumab monotherapy demonstrates an increased ORR with 2000 mg over 1000 mg, but no difference in progression-free survival. No meaningful difference was observed in the overall safety profile across the 2 treatment arms.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/127/1/79/1392335/79.pdf

Reference28 articles.

1. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.;Rai;N Engl J Med,2000

2. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.;Eichhorst;Blood,2009

3. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.;Catovsky;Lancet,2007

4. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.;Flinn;J Clin Oncol,2007

5. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.;Eichhorst;Blood,2006

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024;Journal of the National Comprehensive Cancer Network;2024-04

2. Acute Thrombocytopenia Complicating the Initial Administration of Obinutuzumab: Is It More Frequent Than We Think?;Oncology and Therapy;2024-01-22

3. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review;Current Cancer Therapy Reviews;2024-01

4. Early efficacy and safety of obinutuzumab with chemotherapy in previously untreated patients with follicular lymphoma: A real-world retrospective report of the Polish Lymphoma Research Group;Advances in Clinical and Experimental Medicine;2023-01-05

5. Acalabrutinib and steroid for autoimmune thrombocytopenia due to relapsed chronic lymphocytic leukemia with severe bone marrow infiltration;Journal of Clinical and Experimental Hematopathology;2023